Trevena, Inc. Appoints Mark A. Demitrack as Senior Vice President and Chief Medical Officer
May 21, 2018 at 10:13 pm
Share
Trevena, Inc. announced the appointment of Mark Demitrack, M.D., as Senior Vice President and Chief Medical Officer. Dr. Demitrack brings over 20 years of industry experience at large and small biopharmaceutical companies where he has led numerous CNS programs pre- and post-approval. Prior to joining Trevena, Dr. Demitrack was Vice President, Clinical Strategy at Roivant Sciences, Inc. Previously, Mark was the Chief Medical Officer at Neuronetics, Inc., where he was responsible for the development and approval of the NeuroStar transcranial magnetic stimulation system for the treatment of pharmacoresistant depression, and Medical Director at Lilly Research Labs where he was responsible for the development of CNS drugs from early phase to post-market commercialization and oversaw the development and approval of Cymbalta (duloxetine) for major depression.
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Companyâs pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).
TREVENA, INC. 
